https://cordexbio.com/um171-expanded-cell-therapy-improves-outcomes-compared-with-other-graft-sources-real-world-evidence/ 2023-08-08T11:52:04+00:00 https://cordexbio.com/wp-content/uploads/2023/08/Blood-Advances-Data-EN.png https://cordexbio.com/fr/la-therapie-cellulaire-amplifiee-par-um171-demontre-des-resultats-ameliores-par-rapport-aux-autres-sources-de-greffe-dans-le-contexte-de-vie-reelle/ 2023-08-08T11:53:27+00:00 https://cordexbio.com/wp-content/uploads/2023/08/Blood-Advances-Data-FR.png https://cordexbio.com/fr/excellthera-annonce-la-presentation-de-nouvelles-donnees-sur-lum171-a-la-reunion-ash-2023/ 2023-11-03T11:58:22+00:00 https://cordexbio.com/excellthera-announces-new-um171-data-to-be-presented-at-ash-2023/ 2023-11-03T11:59:58+00:00 https://cordexbio.com/fr/excellthera-annonce-une-denomination-commune-internationale-et-une-nouvelle-designation-de-medicament-orphelin-pour-la-therapie-cellulaire-um171/ 2024-06-04T11:17:58+00:00 https://cordexbio.com/excellthera-announces-international-non-proprietary-name-and-new-orphan-drug-designation-for-um171-cell-therapy/ 2024-06-04T11:19:16+00:00 https://cordexbio.com/fr/zemcelpro-therapie-cellulaire-um171-recoit-un-avis-positif-du-chmp-pour-le-traitement-de-patients-atteints-dun-cancer-du-sang-sans-acces-a-des-cellules-de-donneur-appropriees/ 2025-09-03T21:51:07+00:00 https://cordexbio.com/zemcelpro-um171-cell-therapy-receives-positive-chmp-opinion-for-treatment-of-blood-cancer-patients-without-access-to-suitable-donor-cells/ 2025-09-03T21:51:31+00:00 https://cordexbio.com/zemcelpro-um171-cell-therapy-receives-ec-authorization-as-the-first-and-only-cell-therapy-for-blood-cancer-patients-without-access-to-suitable-donor-cells/ 2025-09-03T21:58:40+00:00 https://cordexbio.com/fr/zemcelpro-therapie-cellulaire-um171-obtient-lautorisation-de-la-ce-en-tant-que-premiere-et-unique-therapie-cellulaire-pour-les-patients-atteints-de-cancers-du-sang-ne-disposant-pas-d/ 2025-09-03T21:58:57+00:00 https://cordexbio.com/fr/zemcelpro-therapie-cellulaire-um171-ameliore-les-resultats-par-rapport-aux-sources-de-greffons-courantes-donnees-europeennes-de-vie-reelle/ 2025-12-19T12:41:05+00:00 https://cordexbio.com/zemcelpro-um171-cell-therapy-improved-outcomes-compared-with-common-graft-sources-european-real-world-evidence/ 2025-12-19T15:30:46+00:00 https://cordexbio.com/fr/zemcelpro-dorocubicel-se-voit-attribue-le-statut-1-du-programme-nub-en-allemagne/ 2026-02-16T12:14:23+00:00 https://cordexbio.com/zemcelpro-dorocubicel-receives-nub-status-1-in-germany/ 2026-02-16T15:08:18+00:00 https://cordexbio.com/zemcelpro-dorocubicel-positive-results-in-high-and-very-high-risk-blood-cancers-to-be-reported-at-the-ebmt-2026-annual-meeting/ 2026-03-10T11:16:14+00:00 https://cordexbio.com/fr/zemcelpro-dorocubicel-des-resultats-positifs-dans-les-cancers-du-sang-a-haut-et-tres-haut-risque-seront-presentes-lors-du-congres-annuel-2026-de-lebmt/ 2026-03-10T11:17:28+00:00